Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Mylan said on Monday the auto-injector EpiPen's pretax profits were 60 percent higher than it told Congress, according to Dow Jones.
Without a tax-related reduction, the pharmaceutical company's profits on the EpiPen two-pack would be about $160, higher than the $100 figure the company gave Congress. The company said any lack of clarity was not intentional.
On Monday, Mylan also submitted to the U.S. Securities and Exchange Commission an analysis of the profitability of the EpiPen in the United States.
"Tax is typically included in a standard profitability analysis and the information provided to Congress has made clear that tax was part of the EpiPen Auto-Injector profitability analysis. In fact, Mylan has provided Congress with a detailed analysis of EpiPen Auto-Injector profitability," Mylan said in a statement.
The company added, "It also is important to note that use of a statutory tax rate for the jurisdiction being analyzed (in this instance, the U.S.) is standard. Just as we did not use a blended global tax rate, we also did not allocate corporate expenses associated with running the business, which would have further reduced its profitability. We believe it is most appropriate, and conservative, to focus entirely on EpiPen(r) Auto-Injector specific costs and associated taxes."
Shares of Mylan dropped more than 1 percent in intraday trading Monday after the news.
Last week, Mylan CEO Heather Bresch testified before a congressional committee about steep price increases on the lifesaving anti-allergic-reaction drug.
House members asked Bresch to provide more evidence for the company's claim that its profits were just $100 for a two-pack of the injectors, despite a $608 list price, according to Dow Jones.
In August, Mylan was scrutinized after consumers saw a five-fold price increase for the EpiPen since 2008.
Mylan's chief told CNBC she was "frustrated" with EpiPen's high prices and said the real problem is with the overall health care system. In response, the company announced plans to increase access to its leading product and offered a generic version at half the price.
This story is developing. Please check back for further updates.